NCT04823624View on ClinicalTrials.gov

MBG453 in Lower Risk MDS

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 27, 2022

Primary Completion Date

November 12, 2024

Study Completion Date

November 1, 2026

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

MBG453

intravenous infusion

Trial Locations (3)

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT04823624 - MBG453 in Lower Risk MDS | Biotech Hunter | Biotech Hunter